514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Authors:
- B. WolpinBWB. Wolpin
- D. HongDHD. Hong
- A. SpiraASA. Spira
- A. StarodubASA. Starodub
- W. ParkWPW. Park
- D. SommerhalderDSD. Sommerhalder
- J. ValerinJVJ. Valerin
- M. BarveMBM. Barve
- S. PunekarSPS. Punekar
- M. PelsterMPM. Pelster
- B. HerzbergBHB. Herzberg
- N. AzadNAN. Azad
- 25 October 2024
- journal article
- abstracts
- Published by Elsevier in European Journal of Cancer
- Vol. 211, S183-S184